|
CardioBreak: Asthma Drug, More on RE-LY
MedPage Today The FDA warned about a slight heart attack and transient ischemic attack risk with the asthma drug omalizumab (Xolair), based on its review of safety studies. The warning will be added to the product label. The RE-LY trialists and drugmaker Boehringer … |
View full post on asthma – Google News